Myelo 2026: Virtual Global Congress on Multiple Myeloma

Myelo 2026

The OncoDaily Multiple Myeloma Congress 2026 is a global virtual medical congress dedicated to multiple myeloma, focusing on early diagnosis, risk stratification, multidisciplinary treatment strategies, and future directions in disease management and control.

Multiple Myeloma remains a significant and growing global health challenge, representing approximately 0.9% of all newly diagnosed cancers and 1.2% of cancer-related deaths worldwide, according to estimates from the World Health Organization (WHO) and the Global Burden of Disease (GBD) study. Recent data suggest that nearly 188,000 new cases are diagnosed each year globally, with over 120,000 deaths attributed to the disease, based on GLOBOCAN and GBD analyses. In the United States alone, around 36,000 new cases are expected in 2026, according to the American Cancer Society, highlighting the continued burden of this plasma cell malignancy.

Event Details

Date: April 23, 2026

Format: Virtual Global Congress

Register

Live Streaming:  YouTube | X

Scientific Program Overview

This focused virtual meeting will explore the full clinical spectrum of multiple myeloma, emphasizing practical, experience-based management in 2026. The program will address contemporary approaches to suspected and newly diagnosed disease through risk-adapted decision-making, as well as evidence-based strategies for relapsed and refractory myeloma. Sessions will examine structured treatment principles that guide daily clinical practice, including the selection of systemic therapies, the sequencing of novel agents, multidisciplinary coordination, and individualized patient care.

The OncoDaily Multiple Myeloma Congress 2026 is designed for hematologists, medical oncologists, hematopathologists, radiologists, radiation oncologists, translational researchers, and oncology trainees seeking a practical and globally informed perspective on multiple myeloma management in 2026.

Chair

ImagesName
Dickran Kazandjian

Dickran Kazandjian (USA)


Professor of Clinical Medicine, Division of Myeloma, Sylvester Myeloma Institute, University of Miami
Associate Director, Sylvester Myeloma Institute, University of Miami
Assistant Director, Clinical Research Services, Office of Clinical Research, Sylvester Comprehensive Cancer Center, Miami, FL

Speakers

NameTopics
Francesco Maura

Francesco Maura (USA)


Associate Director of Myeloma Research Institute at the University of Miami
Mechanisms of Resistance to Immunotherapy
El Hadji Daouda

El Hadji Daouda (Senegal)


Medical Doctor, Department of Hematology and Cellular Therapy at Dalal Jamm Hospital.
Evolution of Multiple Myeloma Management: Advances and Persistent Gaps in Senegal
Al-Ola Abdallah

Al-Ola Abdallah (USA)


Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center
BiTEs in RRMM
Xiaolong Fan

Xiaolong Fan (China)


Professor of Physiology, Key Laboratory of Cell Proliferation and Regulation Biology, Ministry of Education, Beijing Normal University
Plasma Cell Development-Based Prediction of Prognosis and Treatment Response in Individual Multiple Myeloma
Deniz Peker

Deniz Peker (USA)


Professor, Department of Pathology and Laboratory Medicine at at Emory University School
Clonal Evolution in Multiple Myeloma: What MRD Is (and Isn’t) Telling Us
Lisanwork Mikiyas

Lisanwork Mikiyas (Ethiopia)


Medical Doctor, University of Gondar, Lancet General Hospital
Unmasking Multiple Myeloma First Presentation as Pericardial Effusion with Tamponade Physiology: A Case Report
Danielle Roberts

Danielle Roberts (USA)


Physician Assistant with the Bone Marrow and Stem Cell Transplant (BMT) team at Winship Cancer Institute of Emory University
Infection Prophylaxis for Bispecific Therapy
Samer Al Hadidi

Samer Al Hadidi (USA)


Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center
Management of Newly Diagnosed Multiple Myeloma
Shayna Sarosiek

Shayna Sarosiek (USA)


Assistant Professor of Medicine, Department of Medicine Boston University School of Medicine
Waldenstrom Macroglobulinemia: Current and Developing Therapies
Rahul Banerjee

Rahul Banerjee (USA)


Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington

Treating myeloma in the era of MajesTEC-3
Ansh Mehta

Ansh Mehta (USA)


Clinical Assistant Professor in The University of Florida College of Medicine Division of Hematology & Oncology

Role of Measurable Residual Disease in Escalation or Deescalation of Therapy in Myeloma
Linda B. Baughn

Linda B. Baughn (USA)


Co-director of the Clinical Genomics Laboratory, Clinical Cytogeneticist
and Clinical Molecular Geneticist at Laboratory Medicine and Pathology at Mayo Clinic
A Clinician’s Guide to FISH in Multiple Myeloma: Interpretation and Nomenclature Simplified
Yinghui Li

Yinghui Li (Singapore)


Assistant Professor at Nanyang Technological University
Decoding TNFR-Driven Long Non-Coding RNA Functions to Design New Therapeutics for Multiple Myeloma
Benjamin Diamond

Benjamin Diamond (USA)


Assistant Professor at Sylvester Comprehensive Cancer Center
Leveraging Whole Genomes for Identifying Therapeutic Resistance and Residual Disease in Multiple Myeloma
Samvel Bardakhchyan

Samvel Bardakhchyan (Armenia)


Medical Oncologist at Hematology and Oncology Center, Scientific Director of IMMONC, Adult Oncologist at D'clinic
Treatment and Outcomes of Multiple Myeloma in Armenia
Heather Cooper Ortner

Heather Cooper Ortner (USA)


President and CEO of the International Myeloma Foundation

Beyond Survival
Manoj Bhasin

Manoj Bhasin (USA)


Co-Founder and Chief Scientific Advisor at Canomiks, Professor of Pediatrics and Biomedical Informatics at Emory University School of Medicine
Reframing Multiple Myeloma Through the Lens of the Immune Microenvironment
Jenny Ahlstrom

Jenny Ahlstrom (USA)


Founder and CEO of the HealthTree Foundation
Innovating Advocasy: The Tech - Forward Vision of the HealthTree Foundation